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A hallmark of infectious meningitis is the invasion of leukocytes into the subarachnoid
space. In experimental meningitis triggered by tumor necrosis factor–a and interleukin-1b,
the interaction of leukocytes with endothelial cells and the subsequent migration of the cells
through the vessel wall can be inhibited by an antibody to the junctional adhesion molecule
(JAM). In contrast to the cytokine-induced meningitis model, anti-JAM antibodies failed to
prevent leukocyte influx into the central nervous system after infection of mice with Listeria
monocytogenes or lymphocytic choriomeningitis virus. Furthermore, in bacterial meningitis,
anti-JAM IgG antibodies, but not Fab fragments, caused disruption of the endothelium.
Likewise complement-dependent antibody-mediated cytotoxicity was observed in cultured
brain endothelial cells treated with anti-JAM IgG but not with its Fab fragment.
In bacterial meningitis, bacterial cell wall components and
toxins lead to inflammation of the meninges, which frequently
has neurologic sequelae, including impairment of motor and
cognitive functions, seizures, and mental retardation [1]. Influx
of leukocytes into the central nervous system (CNS) is initiated
by cytokine-induced expression of adhesion molecules on endo-
thelial cells and by the production of chemokines that attract
leukocytes into the subarachnoid space [2, 3]. Intracisternal
injection of tumor necrosis factor (TNF)–a, interleukin (IL)–1,
macrophage inflammatory protein (MIP)–1, or MIP-2 leads to
pleocytosis with accumulation of neutrophils in the cerebro-
spinal fluid (CSF) [4]. Previous experimental strategies, which
aimed to prevent the recruitment of leukocytes into the CNS,
have focused on the blockade of interactions of adhesion mol-
ecules on leukocytes and endothelial cells. In rabbits inoculated
intrathecally with pneumococcal antigens, the administration
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of the polysaccharide fucoidin, which interferes with the func-
tion of L-selectin, was found to inhibit leukocyte rolling on
endothelial cells. Leukocyte rolling is a precondition for firm
leukocyte adhesion and subsequent transendothelial migration
[5]. Intravenous injection of antibodies to CD11/CD18, which
is expressed on leukocytes and promotes endothelial adhesion
of the cells, inhibits the development of leukocytosis in rabbits
infected intracisternally with Streptococcus pneumoniae [6].
Antibodies to the intracellular adhesion molecule 1 diminish
the influx of leukocytes into the CSF of rats with pneumococcal
cell wall–induced meningitis [7]. The difficulty of achieving
complete blockade of leukocyte recruitment into the CNS prob-
ably results from a cooperative involvement of endothelial se-
lectins. In mice with inactivation of the P- and E-selectin genes,
only the double knockout mice showed a nearly complete in-
hibition of CNS leukocyte influx triggered by injection of in-
flammatory cytokines [8].
Recently a new target for therapeutic intervention has been
suggested by the demonstration that an antibody to the endo-
thelial cell-cell junctional adhesion molecule (JAM) blocks re-
cruitment of neutrophils into the CNS induced by cytokines
(IL-1b and TNF-a) or the chemokine monocyte chemoattrac-
tant protein (MCP)–3 [9]. JAM seemed especially promising as
a target to limit the inflammatory response in the CNS, because
the transmembrane protein is highly expressed in cells that form
well-organized tight junctions, such as ependymal cells and the
endothelium of the blood-brain barrier [10]. We investigated
the effect of anti-JAM antibodies in a bacterial and a viral
model of meningitis, and we discuss the results with respect to
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the reported results in the cytokine-triggered, self-limited form
of meningitis.
Materials and Methods
Reagents. The monoclonal rat anti–mouse JAM IgG2b anti-
body BV-11 was purified from spent hybridoma medium by ad-
sorption to protein G sepharose (Amersham-Parmacia, Zurich) and
elution with 0.1 M glycine, pH 2.8. The antibody was further pu-
rified by anion-exchange chromatography (Resource Q; Amer-
sham-Pharmacia) at pH 8.0 and was dialyzed in PBS. The antibody
was maintained in sterile aliquots at –807C. The endotoxin content
was determined as 0.42 EU/mg Ig, using a commercial Limulus
amoebocyte assay (KQCL test; BioWhittaker, Verviers, Belgium).
Fab fragments were obtained by papain digestion of BV-11 (1:
200 [w/w]) and purified by cation-exchange chromatography
(MonoS; Amersham-Pharmacia) at pH 6.0, followed by gel-filtra-
tion chromatography (Superdex 75; Amersham-Pharmacia). The
endotoxin content was 0.2 EU/mg Fab. Antibodies and Fab frag-
ment were diluted before injection with endotoxin-free Hanks’ bal-
anced salt solution (HBSS).
Listeria monocytogenes–induced meningitis. Female 12-week-
old C57BL/6 mice purchased from RCC (Fullinsdorf, Switzerland)
were pretreated intraperitoneally (ip) with 200 mg BV-11 IgG in
200 mL HBSS or with 200 mL HBSS as control. After 16 h the
mice were infected intracranially with 600 cfu of L. monocytogenes
in a 25-mL volume. Six, 24, and 48 h after infection, 2 mice each
were anesthetized and perfused with 20 mL Ringer’s solution
(Braun, Sempach, Switzerland). For the 48-h time point, mice were
again given 100 mg BV-11 antibodies at 24 h after infection. CSF
was collected with an elongated Pasteur pipette, and CSF cells were
counted, using a Neubauer hematocytometer. When using the BV-
11 Fab fragment, 4 mice per time point and treatment group were
infected intracranially with 100 cfu of L. monocytogenes in a 25-
mL volume. After 12 and 24 h, mice were perfused, and CSF was
collected. For the 12-h time point, 1000 mg BV-11 Fab was ad-
ministered ip 30 min before infection. For the 24-h time point, 800
mg BV-11 Fab was given 4 h before infection, and 1000 mg BV-11
Fab was given 9 h after infection. Control mice received HBSS.
The percentage of neutrophils, monocytes, and lymphocytes in
CSF was measured on cytospins stained with Diff-Quik (Dade,
Duedingen, Switzerland). In all cases, titers of L. monocytogenes
in brain and liver were determined by plating various dilutions of
organ homogenates on agar plates and counting colonies after 24
h of incubation at 377C.
Lymphocytic choriomeningitis virus (LCMV)–induced meningi-
tis. C57BL/6 mice were treated ip with 185 mg BV-11 IgG in 200
mL HBSS at days 0 and 3. Mice infected with LCMV for a total
of 6 days were additionally given 100 mg BV-11 IgG in 200 mL
HBSS on day 5. HBSS (200 mL) was injected as a control. All mice
were infected intracranially with 30 pfu LCMV Armstrong (pro-
vided by R. Zinkernagel, University of Zurich) in a 25-mL volume
immediately after the first antibody treatment (day 0). At 5 and 6
days after infection, 2 mice per time point and treatment group
were perfused, and CSF was collected as described above.
Culture of murine endothelial cell line bEnd.4. The endothelial
cell line bEnd.4 [11] was provided by K. Ballmer (Friedrich
Miescher Institute, Basel, Switzerland). The cells were grown in
Dulbecco’s MEM (DMEM; Life Technologies, Basel) supple-
mented with 10% fetal calf serum (FCS; Life Technologies), 2 mM
N-acetyl-L-alanyl-L-glutamine (Biochrom, Berlin), and 20 mg/mL
gentamycin (Life Technologies).
Detection of BV-11 antigen expression. For flow cytometric
analysis of JAM expression, bEnd.4 cells were trypsinized from
culture flasks. After being washed in HBSS, 106 cells were resus-
pended in a volume of 100 mL flow cytometry buffer containing
PBS (pH 7.4), 1% FCS, and 0.01% sodium azide and were incu-
bated for 30 min on ice with either BV-11 IgG (rat IgG2b) or an
isotype control (both 1 mg/106 cells), followed by incubation with
a 1:20 diluted R-phycoerythrin (PE)–conjugated F(ab′)2 goat
anti–rat IgG (Serotec; Inotech, Dottikon, Switzerland) for 30 min
on ice. The cells were washed twice in flow cytometry buffer, and
a total of 104 viable cells were analyzed on an Epics profile analyzer
(Coulter, Miami).
BV-11 antibody–mediated cytotoxicity of endothelial cells.
To determine complement-dependent cytotoxicity, bEnd.4 cells
were cultured in 96-well microtiter F-plates (Falcon Plastics, Ox-
nard, CA) at a density of cells/well in 100 mL DMEM42 3 10
containing 10% FCS, 2 mM N-acetyl-L-alanyl-L-glutamine, and 20
mg/mL gentamycin. After 24 h, medium was replaced with 100 mL
cytotoxicity medium (serum-free DMEM and nutrient mixture
Ham’s F10 [Life Technologies] in a 1:1 ratio, containing 2 mM N-
acetyl-L-alanyl-L-glutamine and 20 mg/mL gentamycin). The
bEnd.4 monolayers were then treated for 1 h with the antibodies
(25 mg/mL), followed by the addition of active or heat-inactivated
(567C for 30 min) Low-Tox-M rabbit complement (Cedarlane,
Hornby, Ontario, Canada) at a 1:25 dilution (final assay volume,
150 mL). Cytotoxicity was determined after 3 h by using the
AlamarBlue assay (Lucerna Chem, Lucerne, Switzerland), accord-
ing to the manufacturer’s instructions. Percent specific cytotoxicity
was based on fluorescence units (FU) and was calculated as follows:
specific cytotoxicity p [1 2 (FU of antibody- and complement-
treated cells 2 FU of cell-free cytotoxicity medium)/(FU of com-
plement-treated cells 2 FU of cell-free cytotoxicity medium)] 3
100.
Results
As described elsewhere [12], C57BL/6 mice inoculated intra-
cerebrally with L. monocytogenes developed clinical signs of
disease within 24 h and showed severe illness at 48 h. Pretreat-
ment of mice with anti–JAM antibodies (200 mg ip) neither
prevented nor delayed the development of bacterial meningitis.
On the contrary, mice treated with anti-JAM antibody showed
more-severe clinical signs (hunched posture, immobility, eye
discharge) at 48 h than did saline-treated animals. When ex-
amined histologically at the 48-h time point, antibody-treated
as well as control saline-treated animals showed severe menin-
geal inflammation, characterized by infiltrates in which neutro-
phils predominated. In animals treated with anti–JAM IgG,
the blood vessels of the brain showed severe damage, including
hemorrhages in the brain parenchyma and subarachnoid space
(figure 1). These findings were not noted in saline-treated an-
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Figure 1. Leukocyte infiltration and central nervous system hem-
orrhages in mice with bacterial meningitis treated with BV-11
anti–junctional adhesion molecule (JAM) antibody. Mice were infected
with Listeria monocytogenes and treated with BV-11 anti–JAM IgG.
The photograph shows a brain tissue section stained with hematoxylin-
eosin from day 2 after infection with L. monocytogenes (original mag-
nification, 340).
Figure 2. Pleocytosis in the cerebrospinal fluid of mice infected with
Listeria monocytogenes or lymphocytic choriomeningitis virus (LCMV)
and treated with anti–junctional adhesion molecule (JAM) antibodies.
C57BL/6 mice were infected with L. monocytogenes (A and C) or
LCMV (B) and were treated with BV11 anti–JAM IgG (A and B) or
anti–JAM Fab (C) or HBSS intraperitoneally (see Materials and Meth-
ods); 2 (A and B) or 4 (C) mice per time point or treatment mode
were analyzed. Inflammatory cells in the cerebrospinal fluid were
counted at the indicated time points.
imals (data not shown). Numbers of inflammatory cells in the
CSF did not differ between anti-JAM–treated and saline-
treated mice at 6, 24, and 48 h after infection (figure 2A). At
24 h after infection, the CSF cells of both groups of animals
consisted of ∼90% granulocytes and <10% macrophages, with
only a few lymphocytes (data not shown). In addition, no dif-
ference in Listeria titers was found in brain and liver homog-
enates at any time point (data not shown). These experiments
were repeated 4 times (2 mice per group and time point) with
similar results. Treatment of uninfected control mice with anti-
JAM antibody did not lead to histological changes in the brain
or to CSF pleocytosis 48 h after treatment (data not shown).
Thus, anti–JAM IgG antibodies induced hemorrhages in the
brain parenchyma and subarachnoid space only in the presence
of L. monocytogenes infection.
In contrast to bacterial meningitis, no disruption of the blood
vessel wall was observed in LCMV-induced meningitis treated
with anti-JAM antibodies (data not shown). Signs of disease
at day 6 (weakness, hunched posture, or scruffy fur), as well
as the extent of infiltrates of monocytes and lymphocytes in
the meninges at days 5 and 6, did not differ from those among
HBSS-treated control mice (data not shown). Histological find-
ings correlated with the accumulation of inflammatory cells in
the CSF. No difference in CSF counts was observed between
BV-11 IgG–treated and control mice after infection with LCMV
(figure 2B).
Activation of complement has been well described in bac-
terial infections, including meningitis [13]. The finding that
anti–JAM IgG antibodies caused endothelial damage in bac-
terial, but not viral, meningitis led us to suspect that comple-
ment-dependent cytotoxicity was mediated by binding of the
antibody to the endothelial junction protein. To test this hy-
pothesis, the brain-derived endothelial cell line bEnd.4 was in-
vestigated for expression of JAM and susceptibility to cyto-
toxicity induced by anti–JAM IgG. As shown in figure 3A,
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Figure 3. Brain endothelial cells express junctional adhesion mol-
ecule (JAM) and are susceptible to complement-dependent cytotoxicity
induced by anti–JAM IgG. A, Flow cytometric analysis of bEnd.4 cells
stained with BV-11 anti-JAM IgG or an isotype control. B, Cytotoxicity
of bEnd.4 cells treated with BV-11 anti-JAM IgG in the presence of
rabbit complement. No such effect was seen when either the Fab frag-
ment of the anti-JAM IgG antibody was used or the complement was
heat inactivated (see Materials and Methods).
JAM is expressed at high levels on the surface of bEnd.4 cells.
Treatment of these cells with BV-11 anti–JAM IgG resulted in
almost complete cellular cytotoxicity, the effect being dependent
on the presence of active complement and of the Fc part that
harbors the complement-binding domain of the IgG molecule
(figure 3B).
When the non–complement-binding Fab fragments of the
anti–JAM IgG molecule were injected before and after infection
with L. monocytogenes no intracerebral bleeding was observed
for as long as 48 h after infection, although higher doses (total,
1800 mg) of antibody were administered than in the experiments
where intact anti–JAM IgG had been used (data not shown).
However, the progression of L. monocytogenes–induced disease
in anti-JAM Fab-treated mice was similar to that in control
mice. Histological analysis did not reveal a protective effect of
the anti-JAM Fab antibody on recruitment of leukocytes into
the CNS (data not shown). No differences were found between
anti-JAM Fab-treated mice and controls in the degree of CSF
pleocytosis at 12 and 24 h after infection (figure 2C). This
experiment was repeated 3 times (4 animals per group and time
point) with similar results.
Discussion
This study fails to demonstrate that antibodies to the endo-
thelial tight junction protein JAM protect against leukocyte
accumulation in the meninges or improve the outcome of men-
ingitis in mice infected with either L. monocytogenes or LCMV.
The anti-JAM antibody did not prevent neutrophils, mono-
cytes, or lymphocytes from transmigrating through blood vessel
walls in the CNS. These data differ considerably from those of
previous experiments showing that anti-JAM antibodies atten-
uate experimental meningitis induced by cerebroventricular in-
jection of cytokines (TNF-a and IL-1b) or the chemokine
MCP-3. In the latter model of disease, the antibody reduced
the accumulation of leukocytes in the CSF, meninges, and brain
parenchyma. The contradictory results in the 2 meningitis mod-
els suggest that the mechanisms underlying leukocyte traffic
through the endothelial layer in infectious meningitis are dif-
ferent from those in cytokine-induced meningitis. Recently it
has been shown that treatment of endothelial cells with the
combination of TNF-a and IFN-g, 2 cytokines known to be
expressed in infectious meningitis and to be capable of mod-
ulating transmigration of leukocytes across endothelial cells,
causes disappearance of JAM from intercellular junctions with-
out decreasing the total amount of JAM on the cell surface
[14]. By this mechanism the “glue-like effect” of JAM to stabi-
lize intercellular junctions may be lost in infectious meningitis
but not in the experimental cytokine-induced meningitis model
used by Del Maschio et al. [9]. Therefore, it may be crucial to
use infectious models of meningitis for the development of ther-
apeutic tools to prevent brain inflammation. Our data clearly
show that the strategy of using the tight junction protein JAM
as a target for therapeutic intervention in bacterial meningitis
in humans might be dangerous, because bacteria-induced
activation of the complement system may initiate antibody-
mediated complement-dependent cytotoxicity, thereby leading
to the destruction of the vessel wall and to CNS bleeding. More-
over, the removal of the complement-activating Fc part of the
anti-JAM antibody prevented CNS bleeding but did not show
any beneficial effect in either bacterial or viral meningitis.
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